---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-001774"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:52:02.021711+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "medium"
source: SEC EDGAR
---

# Acumen updates corporate presentation with new EBD data, ACU234 pipeline addition

## Summary
- Nonclinical murine brain exposure data for Enhanced Brain Delivery program presented at CTAD 2025 included.
- Updated fluid biomarker data from Phase 1 INTERCEPT-AD study added to presentation.
- ACU234, a new candidate under the EBD program, now listed in pipeline.
- Presentation posted on company website for use in conferences and communications.

## SEC filing metadata
- accession: 0001628280-26-001774
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000162828026001774/0001628280-26-001774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000162828026001774/abos-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-001774
- JSON: https://secwatch.observer/filing/0001628280-26-001774.json
- Plain text: https://secwatch.observer/filing/0001628280-26-001774.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.